Furthermore, differentiation into pathological or molecular subtypes of bladder cancer, such as basal (CK5/6 positive, CK20 negative) and luminal-like expression profiles, hold the potential to predict beneficial responses towards, e.g., neoadjuvant chemotherapy, which provided the best survival benefit among the basal subtype [55]. The gene discussed is KRT5; the disease is urinary bladder cancer.